3 completed, 1 recruiting, 1 terminated. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Recruiting 1, Terminated 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow EC regimen: new trials by email Literature Review of EC regimen trials Research Report on EC regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel. - Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 203 | 2023-09-05 | 2026-07-15 |
| Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin - Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck | Phase 1 | Completed | AstraZeneca | 32 | 2016-04-28 | 2020-08-20 |
| Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma Carboplatin + etoposide, Thiotepa, Cyclophosphamide + Busilvex - High-risk Medulloblastoma | Phase 1 / Phase 2 | Terminated | Gustave Roussy, Cancer Campus, Grand Paris | 29 | 2013-09-14 | 2024-05-24 |
| Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy F-627, EC regimen - Neutropenia, Breast Cancer | Phase 1 | Completed | EVIVE Biotechnology | 18 | 2012-12-01 | 2024-02-23 |
| A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) Obatoclax, Carboplatin/etoposide - Extensive-stage Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Gemin X | 218 | 2008-05-01 | 2016-07-21 |
Small Cell Lung Carcinoma (3) · Breast Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Pancreatic Ductal (1) · Esophageal Squamous Cell Carcinoma (1) · Fallopian Tube Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neutropenia (1) · Ovarian Neoplasms (1) · Peritoneal Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
AstraZeneca (1) · EVIVE Biotechnology (1) · Gemin X (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Phanes Therapeutics (1)
United States (2) · Bulgaria (1) · Canada (1) · Czechia (1) · France (1) · Hungary (1) · India (1) · Japan (1) · Poland (1) · Romania (1) · Serbia (1) · South Korea (1) · United Kingdom (1)
Christelle Dufour, MD (1) · Jean Viallet, MD (1) · Junning Cao, Professor (1)